uniQure (NASDAQ:QURE) Receives $33.88 Consensus Target Price from Analysts

Shares of uniQure (NASDAQ:QURE) have been given an average recommendation of “Buy” by the ten analysts that are covering the company, MarketBeat reports. Two investment analysts have rated the stock with a hold rating, six have issued a buy rating and two have issued a strong buy rating on the company. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $33.88.

A number of equities research analysts recently weighed in on QURE shares. StockNews.com upgraded shares of uniQure to a “sell” rating in a report on Wednesday, December 11th. Royal Bank of Canada boosted their price target on uniQure from $14.00 to $20.00 and gave the company an “outperform” rating in a report on Wednesday, December 11th. Guggenheim restated a “buy” rating on shares of uniQure in a report on Wednesday, December 11th. Cantor Fitzgerald increased their price target on uniQure from $28.00 to $58.00 and gave the stock an “overweight” rating in a research report on Tuesday, December 10th. Finally, Leerink Partners raised their price target on uniQure from $26.00 to $44.00 and gave the company an “outperform” rating in a research note on Wednesday, December 11th.

Insider Transactions at uniQure

In other news, CEO Matthew C. Kapusta sold 3,418 shares of the firm’s stock in a transaction on Monday, December 9th. The stock was sold at an average price of $7.63, for a total value of $26,079.34. Following the completion of the sale, the chief executive officer now owns 597,915 shares of the company’s stock, valued at $4,562,091.45. This trade represents a 0.57 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 4.74% of the company’s stock.

Institutional Investors Weigh In On uniQure

Institutional investors have recently added to or reduced their stakes in the business. American Century Companies Inc. raised its position in shares of uniQure by 14.6% in the 2nd quarter. American Century Companies Inc. now owns 67,699 shares of the biotechnology company’s stock valued at $303,000 after purchasing an additional 8,642 shares during the last quarter. Total Clarity Wealth Management Inc. purchased a new stake in shares of uniQure during the second quarter valued at $74,000. Vanguard Personalized Indexing Management LLC increased its position in shares of uniQure by 21.0% in the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 13,301 shares of the biotechnology company’s stock valued at $59,000 after acquiring an additional 2,306 shares during the period. Marshall Wace LLP purchased a new position in uniQure in the 2nd quarter worth $175,000. Finally, Cubist Systematic Strategies LLC raised its stake in uniQure by 130.9% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 25,494 shares of the biotechnology company’s stock worth $114,000 after acquiring an additional 14,454 shares during the last quarter. Institutional investors and hedge funds own 78.83% of the company’s stock.

uniQure Stock Up 5.7 %

Shares of NASDAQ:QURE opened at $13.99 on Thursday. The company has a debt-to-equity ratio of 0.92, a current ratio of 6.51 and a quick ratio of 6.51. The business has a 50 day simple moving average of $11.83 and a two-hundred day simple moving average of $8.24. uniQure has a 1 year low of $3.73 and a 1 year high of $19.18. The firm has a market capitalization of $681.91 million, a PE ratio of -2.82 and a beta of 0.41.

uniQure (NASDAQ:QURE) last announced its quarterly earnings data on Tuesday, November 5th. The biotechnology company reported ($0.91) EPS for the quarter, beating the consensus estimate of ($1.12) by $0.21. uniQure had a negative return on equity of 188.82% and a negative net margin of 837.80%. The company had revenue of $2.29 million for the quarter, compared to the consensus estimate of $2.73 million. On average, equities analysts predict that uniQure will post -3.74 EPS for the current year.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.